Posts

Sanofi Reports Positive but Mixed Phase 3 Results for Amlitelimab in Atopic Dermatitis with OX40L Targeting and Kaposi's Sarcoma Case

on
Sanofi announced positive Phase 3 results from COAST 1, COAST 2, and SHORE studies for amlitelimab, an anti-OX40 ligand antibody, showing improvements in skin clearance and itch reduction in moderate-to-severe atopic dermatitis patients aged 12+ compared to placebo. 1 2 3 COAST 1 met primary and key secondary endpoints (vIGA-AD 0/1, EASI-75, PP-NRS ≥4); COAST 2 met primary but mixed secondaries (EASI-75 and PP-NRS significant, vIGA-AD not); SHORE met all endpoints with topical therapies. 2 3 5 Data indicate progressive efficacy without plateau at Week 24, supporting Q12W dosing potential; long-term Atlantis Phase 2 data showed continued improvements to Week 52. 2 3 5 6 Results described as mixed by some analysts, falling short of Dupixent benchmarks despite meeting endpoints. 5 One patient with risk factors developed cutaneous Kaposi's sarcoma in Atlantis study, stopped treatment, and is recovering; well-tolerated overall. 5 Sources: 1. https://www.marketscreener.com/ne...

Merck Advances Winrevair to Phase 3 with Preference for Lower Dose in Rare Heart Failure Trial

on

Eli Lilly and Insilico Medicine Announce $2.75 Billion AI-Driven Drug Discovery Collaboration

on

Biogen Announces Positive Phase 2 Results for Litifilimab in Cutaneous Lupus Erythematosus from AMETHYST Study

on

"A Bit of a Surprise": Kardigan's Tonlamarsen Shows No Blood Pressure Benefit from Repeat Dosing in Phase 2 Trial

on

AstraZeneca's Tozorakimab Achieves Phase 3 Success in Broader COPD Population

on

AstraZeneca's In Vivo CAR-T ESO-T01 Shows Promise in Multiple Myeloma with Remissions but One Death in China Trial

on

Kailera Therapeutics Files for Nasdaq IPO to Fund Obesity Drug Pipeline Licensed from China Partner

on

Anumana Secures FDA Clearance for First-of-Its-Kind ECG-AI Algorithm for Early Detection of Pulmonary Hypertension

on

FDA Approves Novo Nordisk's Awiqli: First Once-Weekly Basal Insulin for Type 2 Diabetes

on

Recordati Confirms Non-Binding €10.9 Billion Full Takeover Offer from CVC Capital Partners

on

"We need to put some bad ideas to bed": Inside Incubate's battles for biotech on Capitol Hill

on

Novartis Agrees to Acquire Excellergy for Up to $2 Billion to Bolster Allergy Portfolio with Potential Xolair Successor

on